Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146574 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01146574 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 50 participants.
The verdict
NCT01146574, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is the first study in hemodialysis subjects with anemia to evaluate the pharmacokinetics, safety, efficacy, tolerability, and pharmacodynamics of sotatercept (ACE-011)
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Sotatercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-06-30 |
| Est. Completion | 2016-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01146574
The ClinicalTrials.gov registry entry for NCT01146574 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01146574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01146574 about?
NCT01146574 is a clinical study titled "A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.". This is the first study in hemodialysis subjects with anemia to evaluate the pharmacokinetics, safety, efficacy, tolerability, and pharmacodynamics of sotatercept (ACE-011)
What is the current status of trial NCT01146574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2010-06-30. Estimated completion is 2016-03-07.
What interventions are being tested in trial NCT01146574?
The interventions under investigation include: Placebo (BIOLOGICAL), Sotatercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT01146574?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.